Regeneron price target lowered to $650 from $700 at Citi
Citi analyst Geoff Meacham lowered the firm's price target on Regeneron (REGN) to $650 from $700 and keeps a Buy rating on the shares. The company reported mixed itepekimab Phase 3 COPD results in former smokers, the analyst tells investors in a research note. The firm says that wWhile Aerify-1 met its primary endpoint in both dosing arms, Aerify-2 failed to achieve statistical significance improvement at week 52. While Aerify-1 was positive, the path to approval is unclear, contends Citi.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
Women on Weight-Loss Drugs Warned of Surprise ‘Ozempic Babies'
Women taking popular weight-loss drugs have been urged to use effective contraception while taking the medication amid reports of a so-called "Ozempic babies" phenomenon. The advice was issued by the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA), an executive agency of the Department of Health and Social Care, on Thursday. Newsweek reached out to the U.S. Department of Health and Human Services for comment via email. Demand for weight-loss drugs, including GLP-1 medications such as Ozempic, Wegovy, and Mounjaro, has surged in the United States. In May 2024, a KFF Health Tracking Poll found that approximately 6 percent of American adults—about 15 million people—were using GLP-1 agonists such as Ozempic, either for diabetes treatment or weight loss. Some experts have cautioned that women should use effective contraception while taking these medications amid reports that they may be linked to an increase in unexpected pregnancies, The Guardian reported last May. The MHRA issued its alert after receiving 40 reports related to pregnancies while using "GLP-1 medicines," which are known by the brand names Ozempic, Mounjaro, Wegovy, Saxenda, and Victoza. Ozempic and Wegovy contain semaglutide, which mimics the GLP-1 hormone to increase insulin, slow digestion, and suppress appetite. Mounjaro contains tirzepatide, which acts on an additional hormone related to blood sugar and appetite control. The MHRA warned that Mounjaro may reduce the effectiveness of oral contraceptives in people who are overweight. It received 26 pregnancy-related reports for Mounjaro alone. "Therefore, those taking Mounjaro who are overweight and are using an oral form of contraception are advised to also use a non-oral form of contraception," the agency said. "This only applies to those taking Mounjaro and is especially important for the four weeks after starting Mounjaro and after any dose increase." Hundreds of women have shared personal accounts of unplanned pregnancies while using these medications in online groups, including the Facebook group "I got pregnant on Ozempic." "My ozempic baby...I see so many posts about ozempic and asking for "stories or side effects," but I never see anyone warning about pregnancy... lol," one woman shared on Facebook. "If you don't know, I got pregnant on ozempic and so many other women have too..I was on ozempic for 6 weeks & found out I was pregnant. I was so scared, google had me frightened I would miscarry because of the ozempic. I then came across a group called 'I got pregnant on ozempic'. I started reading all of these stories about women fighting infertility and getting pregnant on ozempic." The Food and Drug Administration has not yet issued similar advisories in the United States. MHRA Chief Safety Officer Dr. Alison Cave said: "Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments. They are not a quick fix to lose weight, and have not been assessed to be safe when used in this way. "Our guidance offers patients a 'one stop shop' for our up-to-date advice on how to use these powerful medicines safely. "This guidance should not be used as a substitute to reading the patient information leaflet or having a conversation with a healthcare professional as part of the prescribing process." Dr. Ilana Ressler, a reproductive endocrinologist at Illume Fertility, told Interesting Engineering on May 22: "There is this phenomenon of Ozempic what I think what's happening is women who may not have been ovulating before with the improvements that the medication is bringing on, that might be helping them to ovulate more regularly and they might be more likely to conceive while on the medication than not—so it is recommended to avoid pregnancy while taking the medication." Dr. Zuri A. Murrell, in a video on X last year: "There is nothing magical about the medicine that's in Ozempic that helps you get pregnant. But what it does is that a lot of times, when people can't, it's because of a hormone weight imbalance. "And so, when you lose weight, and sometimes when you lose weight rapidly, the hormones and the new you aren't in concert. Or they really are in concert, and guess what can happen, pregnancy. "So, it's not the Ozempic itself, it is actually the balancing out of your hormones. That means that you've lost fat, and that the body actually for you is working like it should. So just remember, Ozempic is not something that somebody takes and 'I'm pregnant.' What it does do is cause your body and hormone level to be more in sync and more likely that you can." It remains unclear whether the FDA will follow the MHRA's lead in issuing similar warnings or guidance on contraception. Related Articles Therapist Asks Who Women 'Want To Be Skinny For'-Her Theory Is Eye-OpeningThe Good Life: Weight Loss Wins, But at What Cost?How Ozempic and Other GLP-1 Drugs Are Eating Away at Body PositivityGen Z Is Leading a New Weight Loss Trend: Ozempic Microdosing 2025 NEWSWEEK DIGITAL LLC.
Yahoo
an hour ago
- Yahoo
Global Virus Network Issues Scientific Guidance on New COVID-19 Variant NB.1.8.1 and Vaccine Protection
Scientific collaboration, accurate public communication, and continued investment in prevention tools are critical in navigating the evolving COVID-19 landscape TAMPA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- The Global Virus Network (GVN) is closely monitoring the emergence of a newly identified SARS-CoV-2 variant, NB.1.8.1, a sublineage of the Omicron family. This variant was first identified in January 2025 and has rapidly spread across Asia and into other regions, including parts of the United States. The World Health Organization (WHO) has designated NB.1.8.1 as a Variant Under Monitoring due to its increasing prevalence and potential public health implications. Based on current evidence, GVN advises vigilance, not alarm, and reinforces the critical role of vaccination in preventing severe disease and death. Similar to previous Omicron subvariants, NB.1.8.1 contains spike protein mutations associated with increased transmissibility. However, no evidence suggests that NB.1.8.1 causes more severe illness or significantly evades vaccine-induced or natural immunity. Early laboratory and clinical data indicate that updated COVID-19 vaccines, including bivalent and XBB-based boosters, protect against severe outcomes such as hospitalization and death. There is no evidence at this time that NB.1.8.1 causes more severe illness than previous variants. Breakthrough infections may occur, particularly among individuals with waning immunity or those who are unvaccinated. Nevertheless, vaccines remain highly effective in reducing serious illness and death. Antiviral treatments such as nirmatrelvir/ritonavir (Paxlovid) and remdesivir demonstrate efficacy against a range of Omicron subvariants, including BQ.1, BQ.1.1, and XBB.1.5. NB.1.8.1 has been linked to significant increases in COVID-19 cases across several countries. According to the WHO, as of May 18, 2025, the NB.1.8.1 variant has been identified in 22 countries, accounting for 10.7% of global SARS-CoV-2 sequences submitted to the Global Initiative on Sharing All Influenza Data (GISAID) during epidemiological week 17 (April 21–27, 2025). This marks a significant increase from 2.5% four weeks prior. As of June 4, 2025, India reported 4,302 active COVID-19 infections, with nearly 300 new cases recorded within the previous 24 hours. States such as Delhi, Uttar Pradesh, West Bengal, Gujarat, and especially Kerala have experienced a steady rise in cases. During the week of April 27 to May 3, 2025, nearly 6,000 individuals in Taiwan sought medical assistance at hospitals due to COVID-19-related symptoms. This marked a 78% increase from the previous week and represented the fourth consecutive week of rising case numbers. As of early June 2025, in the U.S., more than a dozen cases of the NB.1.8.1 subvariant have been identified in Washington State. The variant was first detected in the U.S. between late March and early April through routine screenings of international travelers at airports in California, Washington State, Virginia, and New York. Subsequent cases have been reported in Ohio, Rhode Island, and Hawaii. In the U.S., there have been about 300 deaths per week from COVID-19 in 2025 through May. Periodic summer surges are anticipated, consistent with seasonal patterns observed in previous years. GVN Supports the Following COVID-19 Vaccine Recommendations: Adults aged 65 and older, and individuals with underlying conditions, should receive an updated COVID-19 booster tailored to circulating variants. All individuals 6 months and older, including children and adolescents, are encouraged to stay current with vaccinations, especially ahead of the fall and winter respiratory seasons. Children 6 months to 17 years of age should receive an age-appropriate, updated COVID-19 vaccine dose if they have not already done so within the past year, as protection from earlier vaccines may wane over time. Pediatric vaccination helps prevent severe outcomes, including hospitalization and multisystem inflammatory syndrome in children (MIS-C). Pregnant individuals are strongly encouraged to stay current on COVID-19 vaccination. Vaccination during pregnancy reduces the risk of COVID-19 hospitalization in infants by 61% and protects newborns for up to six months after birth—an especially important window given the high rate of emergency department visits for COVID-19 among infants. Studies have consistently shown that infection during pregnancy increases the risk of preterm birth, miscarriage, fetal death, and long-term neurodevelopmental issues. No safety concerns have been identified regarding vaccination in pregnancy or neonatal outcomes. Those not receiving a COVID-19 booster in the past year should consult a healthcare provider about updated vaccine timing and eligibility. Co-administration of COVID-19 and influenza vaccines is recommended when appropriate. Side effects from both COVID-19 and influenza vaccines are rare, and the cost-benefit of vaccination is heavily in favor of vaccination. The principal benefits of vaccination are preventing severe disease, rather than preventing infection itself. The rapid global spread of NB.1.8.1 underscores the ongoing need for proactive surveillance, timely data sharing, and pandemic preparedness. The appearance of new variants is expected and does not signal a public health emergency. Instead, it is a call to action for continued scientific vigilance and proactive health measures. GVN reiterates that this is an opportunity to prepare, not a reason to panic. Scientific collaboration, accurate public communication, and continued investment in prevention tools will remain critical in navigating the evolving COVID-19 landscape. Media Contact: Nora Samaranayakensamaranayake@ About the Global Virus Network The Global Virus Network (GVN) is a worldwide coalition comprising 80+ Virology Centers of Excellence and Affiliates across 40+ countries, whose mission is to facilitate pandemic preparedness against viral pathogens and diseases that threaten public health globally. GVN advances knowledge of viruses through (i) data-driven research and solutions, (ii) fostering the next generation of virology leaders, and (iii) enhancing global resources for readiness and response to emerging viral threats. GVN provides the essential expertise required to discover and diagnose viruses that threaten public health, understand how such viruses spread illnesses, and facilitate the development of diagnostics, therapies, and treatments to combat them. GVN coordinates and collaborates with local, national, and international scientific institutions and government agencies to provide real-time virus informatics, surveillance, and response resources and strategies. GVN's pandemic preparedness mission is achieved by focusing on Education & Training, Qualitative & Quantitative Research, and Global Health Strategies & Solutions. The GVN is a non-profit 501(c)(3) organization. For more information, please visit in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
The LGL Group, Inc. Adds Over-Subscription Privilege to Outstanding Warrants, Files Post-Effective Amendment to the Related Registration Statement
Orlando, Florida--(Newsfile Corp. - June 5, 2025) - The LGL Group, Inc. (NYSE American: LGL) (NYSE American: LGL WS) ("LGL Group" or the "Company") today announced that is has added an Over-Subscription Privilege to its outstanding warrants to purchase common stock which were originally issued as a dividend to LGL Group stockholders on November 16, 2020 (the "Warrants"). The Company will file with the Securities and Exchange Commission (the "SEC") a post-effective amendment to its related registration statement on Form S-1 that, once declared effective, will permit holders to exercise the Warrants up and until to their expiration at the close of business on November 16, 2025, a Sunday, which allows holders to exercise the Warrants by the close of business on November 17, 2025 (the "Expiration Date"). Current Exercise Price of Warrants As a result of the previously announced downward adjustment of the exercise price triggered by the spinoff of M-tron Industries, Inc., five (5) Warrants are exercisable to purchase one share of common stock at an exercise price of $4.75. Addition of Over-Subscription Privilege The Company has amended the warrant agreement to add an Over-Subscription Privilege that will from and after close of business on October 16, 2025 (the "Over-Subscription Commencement Date") until the Expiration Date allow warrant holders to subscribe for additional shares of common stock that remain unsubscribed as a result of any unexercised Warrants. The total number of shares of common stock that will be available to all holders who exercise their Warrants and elect the Over-Subscription Privilege will be the number of shares which are not subscribed for as of the Expiration Date pursuant to the basic warrant exercise rights of all holders. Holders that exercise the Warrants prior to the Over-Subscription Commencement Date will not be entitled to subscribe for additional shares pursuant to the Over-Subscription Privilege. Further information concerning how to exercise LGL Group Warrants can be found on the Warrant FAQ page of the Company's website at None of the Company, its board of directors or employees has made or is making any representation or recommendation to any holder of the Warrants as to whether to exercise or refrain from exercising any Warrants. Pending Registration LGL Group will file with the SEC a post-effective registration statement on Form S-1 (No. 333-158319) that includes a prospectus relating to the offering of the shares of common stock issuable upon exercise of the Warrants. The securities being registered may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. Copies of the prospectus for the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at Warrant Agent Computershare Inc. and its wholly-owned subsidiary, Computershare Trust Company, N.A. (together "Computershare"), serve as the Company's warrant agent. All holders of LGL Group's warrants should direct all questions concerning the Warrants to Computershare at: By telephone (within the U.S., U.S. territories and Canada): 1-800-546-5141 By telephone (outside the U.S., U.S. territories and Canada): 1-781-575-2765 If delivering by U.S. mail: Computershare Trust Company, N.A.c/o Voluntary Corporate ActionsP.O. Box 43011Providence, RI 02940-3011 If delivering by courier: Computershare Trust Company, N.A.c/o Voluntary Corporate Actions150 Royall Street, Suite VCanton, MA 02021 The warrant FAQs relating to their original issuance and amendments made to date can be found: About The LGL Group, Inc. The LGL Group, Inc. ("LGL," "LGL Group," or the "Company") is a holding company engaged in services, merchant investment and manufacturing business activities. Precise Time and Frequency, LLC ("PTF") is a globally positioned producer of industrial Electronic Instruments and commercial products and services. Founded in 2002, PTF operates from our design and manufacturing facility in Wakefield, Massachusetts. Lynch Capital International LLC is focused on the development of value through investments. LGL Group was incorporated in 1928 under the laws of the State of Indiana, and in 2007, the Company was reincorporated under the laws of the State of Delaware as The LGL Group, Inc. We maintain our executive offices at 2525 Shader Road, Orlando, Florida 32804. Our telephone number is (407) 298-2000. Our Internet address is LGL Group common stock and warrants are traded on the NYSE American under the symbols "LGL" and "LGL WS," respectively. LGL Group's business strategy is primarily focused on growth through expanding new and existing operations across diversified industries. The Company's engineering and design origins date back to the early 1900s. In 1917, Lynch Glass Machinery Company ("Lynch Glass"), the predecessor of LGL Group, was formed and emerged in the late 1920s as a successful manufacturer of glass-forming machinery. Lynch Glass was then renamed Lynch Corporation ("Lynch") and was incorporated in 1928 under the laws of the State of Indiana. In 1946, Lynch was listed on the "New York Curb Exchange," the predecessor to the NYSE American. The Company has a had a long history of owning and operating various business in the precision engineering, manufacturing, and services sectors. Cautionary Note Concerning Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as those pertaining to the Company's financial condition, results of operations, business strategy and financial needs. All statements other than statements of current or historical fact contained in this press release are forward-looking statements. The words "believe," "expect," "anticipate," "should," "plan," "will," "may," "could," "intend," "estimate," "predict," "potential," "continue" or the negative of these terms and similar expressions, as they relate to LGL Group, are intended to identify forward-looking statements. These forward-looking statements are largely based on current expectations and projections about future events and financial trends that may affect the financial condition, results of operations, business strategy and financial needs of the Company. They can be affected by inaccurate assumptions, including the risks, uncertainties and assumptions described in the filings made by LGL Group with the Securities and Exchange Commission ("SEC"), including those risks set forth under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025. In light of these risks, uncertainties and assumptions, the forward-looking statements in this press release may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements. When you consider these forward-looking statements, you should keep in mind these risk factors and other cautionary statements in this press release. These forward-looking statements speak only as of the date of this press release. LGL Group undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. No Offer or Solicitation This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy common stock of the Company or any other securities and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. ### Contact: The LGL Group, To view the source version of this press release, please visit
